Delta-Fly Pharma, Inc. (TYO:4598)

Delta-Fly Pharma Cash Flow Statement

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Net Income	-1,718	-1,426	-1,325	-964	-859
Depreciation & Amortization	1	1	1	1	2
Other Operating Activities	-3	-2	-2	5	-8
Change in Accounts Receivable	-	-	-	-	110
Change in Accounts Payable	-82	117	20	3	-14
Change in Other Net Operating Assets	-32	31	3	15	43
Operating Cash Flow	-1,834	-1,279	-1,303	-940	-726
Capital Expenditures	-	-1	-	-	-
Other Investing Activities	-	1	-	-	-
Long-Term Debt Issued	-	-	400	-	-
Long-Term Debt Repaid	-	-	-400	-	-5
Net Debt Issued (Repaid)	-	-	-	-	-5
Issuance of Common Stock	756	1,354	882	120	881
Other Financing Activities	-	499	-	-1	-1
Financing Cash Flow	756	1,853	882	119	875
Foreign Exchange Rate Adjustments	-	-1	-3	-	-3
Miscellaneous Cash Flow Adjustments	-	-1	-	1	-2
Net Cash Flow	-1,078	572	-424	-820	144
Free Cash Flow	-1,834	-1,280	-1,303	-940	-726
Free Cash Flow Margin	-	-	-	-313.33%	-242.00%
Free Cash Flow Per Share	-208.41	-178.00	-229.96	-173.54	-157.68
Cash Income Tax Paid	2	2	3	-2	8
Levered Free Cash Flow	-1,193	-743.88	-806.88	-575.63	-403.5
Unlevered Free Cash Flow	-1,193	-743.88	-806.88	-575.63	-403.5
Change in Net Working Capital	126	-133	-14	-24	-127

Source: S&P Global Market Intelligence. Standard template. Financial Sources.